PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

TACE plus percutaneous chemotherapy-lipiodol treatment of unresectable pedunculated hepatocellular carcinoma.

Abstract Pedunculated hepatocellular carcinoma (P-HCC) is rare type of HCC. The study aimed to evaluate the clinical features and outcomes of unresectable P-HCC treated with transcatheter arterial chemoembolization (TACE) and percutaneous chemotherapeutic agents lipiodol emulsion (CALE) injection. The clinical features and outcomes of 25 patients with unresectable P-HCC treated with TACE plus percutaneous CALE injection were retrospectively reviewed, and factors associated with outcomes were analyzed. Comparison with nonpedunculated unresectable HCC was also performed. Patients underwent a median of 4 TACE sessions and received a median of 2 percutaneous CALE injections. The 1-, 2-, 3-, and 5-year actuarial survival rates were 78.9%, 52.6%, 42.1%, and 12.0%, respectively, for patients with P-HCC, and median survival was 27 months (95% confidence interval, 22.6-43.2 months). Patients with P-HCC had better overall survival than those with nonpedunculated HCC (NP-HCC) (Pā€Š=ā€Š.002). Vascular invasion and abdominal lymph node metastasis were poor prognostic factors for overall survival in patients with P-HCC. TACE plus percutaneous CALE injection is a safe and effective treatment for unresectable P-HCC. Patients with unresectable P-HCC might have better overall survival than those with NP-HCC after TACE plus percutaneous CALE injection. However, their prognosis remains poor.
PMID
Related Publications

Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients.

Single-step multimodal locoregional treatment for unresectable hepatocellular carcinoma: balloon-occluded percutaneous radiofrequency thermal ablation (BO-RFA) plus transcatheter arterial chemoembolization (TACE).

Lipiodol trans-arterial chemoembolization of hepatocellular carcinoma with idarubicin: first experience.

Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin-Lipiodol emulsion.

Clinical significance and risk factors of postembolization fever in patients with hepatocellular carcinoma.

Authors

Mayor MeshTerms

Chemoembolization, Therapeutic

Keywords
Journal Title medicine
Publication Year Start




PMID- 28746230
OWN - NLM
STAT- MEDLINE
DA  - 20170726
DCOM- 20170807
LR  - 20170807
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 30
DP  - 2017 Jul
TI  - TACE plus percutaneous chemotherapy-lipiodol treatment of unresectable
      pedunculated hepatocellular carcinoma.
PG  - e7650
LID - 10.1097/MD.0000000000007650 [doi]
AB  - Pedunculated hepatocellular carcinoma (P-HCC) is rare type of HCC. The study
      aimed to evaluate the clinical features and outcomes of unresectable P-HCC
      treated with transcatheter arterial chemoembolization (TACE) and percutaneous
      chemotherapeutic agents lipiodol emulsion (CALE) injection. The clinical features
      and outcomes of 25 patients with unresectable P-HCC treated with TACE plus
      percutaneous CALE injection were retrospectively reviewed, and factors associated
      with outcomes were analyzed. Comparison with nonpedunculated unresectable HCC was
      also performed. Patients underwent a median of 4 TACE sessions and received a
      median of 2 percutaneous CALE injections. The 1-, 2-, 3-, and 5-year actuarial
      survival rates were 78.9%, 52.6%, 42.1%, and 12.0%, respectively, for patients
      with P-HCC, and median survival was 27 months (95% confidence interval, 22.6-43.2
      months). Patients with P-HCC had better overall survival than those with
      nonpedunculated HCC (NP-HCC) (P = .002). Vascular invasion and abdominal lymph
      node metastasis were poor prognostic factors for overall survival in patients
      with P-HCC. TACE plus percutaneous CALE injection is a safe and effective
      treatment for unresectable P-HCC. Patients with unresectable P-HCC might have
      better overall survival than those with NP-HCC after TACE plus percutaneous CALE 
      injection. However, their prognosis remains poor.
FAU - Huang, Dexiao
AU  - Huang D
AD  - aDepartment of Medical Imaging, The 2nd Affiliated Hospital of Shantou University
      Medical College, Shantou bDepartment of Interventional Radiology, Nanfang
      Hospital, Southern Medical University, Guangzhou, Guangdong, PR China.
FAU - Chen, Yong
AU  - Chen Y
FAU - Chen, Shuo
AU  - Chen S
FAU - Zeng, Qingle
AU  - Zeng Q
FAU - Zhao, Jianbo
AU  - Zhao J
FAU - Wu, Renhua
AU  - Wu R
FAU - Li, Yanhao
AU  - Li Y
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antineoplastic Agents)
RN  - 8008-53-5 (Ethiodized Oil)
SB  - AIM
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/*administration & dosage
MH  - Carcinoma, Hepatocellular/diagnostic imaging/*therapy
MH  - *Chemoembolization, Therapeutic
MH  - Ethiodized Oil/*administration & dosage
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Liver Neoplasms/diagnostic imaging/*therapy
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2017/07/27 06:00
MHDA- 2017/08/08 06:00
CRDT- 2017/07/27 06:00
AID - 10.1097/MD.0000000000007650 [doi]
AID - 00005792-201707280-00061 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Jul;96(30):e7650. doi: 10.1097/MD.0000000000007650.